AbCellera Biologics Inc.
ABCL· Nasdaq
Released May 7, 2024, after the close
10-Q filed May 7, 2024, 37 days after period end · 0001628280-24-021159
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $9.95M | $12.19M | $316.58M | $202.74M |
| Net Income | -$40.61M | -$40.11M | $168.57M | $117.22M |
| EPS Diluted |
AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR
| -$0.14 |
| -$0.14 |
| $0.54 |
| $0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.